Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

Pashtoon M. Kasi, Hussein A. Tawbi, Chester V. Oddis, Hrishikesh S. Kulkarni

Research output: Contribution to journalReview article

63 Scopus citations

Abstract

The advent of biologic agents has provided a more specific and targeted approach to the treatment of various hematological malignancies and other autoimmune disorders. Such biologic agents have been relatively well tolerated with fewer adverse events reported as compared with many other chemotherapeutic agents. Rituximab is a monoclonal antibody to the B-cell marker CD20 and is a common biologic agent widely used for the treatment of B-cell lymphoma, lymphoproliferative disorders, and inflammatory conditions that are refractory to conventional treatment, including rheumatoid arthritis and some vasculitides. However, through randomized controlled trials and post-marketing surveillance, an increasing number of serious adverse events are being associated with the use of rituximab, often leading to or complicating an intensive care unit admission. The purpose of this review is to focus on the severe complications that are associated with the use of rituximab and that require critical care. Management and prevention strategies for the most common complications along with some examples of its uses within the critical care setting are also discussed.

Original languageEnglish
Article number231
JournalCritical Care
Volume16
Issue number4
DOIs
StatePublished - Aug 31 2012
Externally publishedYes

Fingerprint Dive into the research topics of 'Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective'. Together they form a unique fingerprint.

  • Cite this